Home > Boards > US Listed > Cannabis >

Zynerba Pharmaceuticals (ZYNE)

ZYNE RSS Feed
Add ZYNE Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 10/21/2019 9:47:41 PM - Followers: 104 - Board type: Free - Posts Today: 5


Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Company is evaluating approximately two product candidates, ZYN002 and ZYN001, in over five indications. The Company intends to study ZYN002 in patients with refractory epilepsy, osteoarthritis and Fragile X syndrome. The Company's ZYN002 is synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. ZYN002 is being developed as a clear that is designed to provide controlled drug delivery with once- or twice-daily dosing. ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through a patch. The Company intends to test the ZYN001 patch for application to the arm, back and thigh. The Company intends to study ZYN001 in patients with fibromyalgia and peripheral neuropathic pain.

Investor Relations

Corporate Profile

Zynerba (NASDAQ: ZYNE) is pioneering the development of patent-protected, next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery. Its two lead product candidates in development include ZYN002 and ZYN001, which are being evaluated in five indications. ZYN002 is the first and only synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. In June 2016, the company initiated the STAR 1 Phase 2 clinical trial in refractory epilepsy patients and in August 2016, initiated the STOP Phase 2 clinical trial in patients with osteoarthritis of the knee. A Phase 2 clinical trial in patients with Fragile X syndrome will be initiated in the second half of 2016. 

ZYN001, a prodrug of THC that enables transdermal delivery through the skin and circulatory system via a patch, is in preclinical development. A Phase 1 clinical trial is planned in the first half of 2017.

In August 2015, Zynerba completed an initial public offering, raising net proceeds of $42.1 million. As of June 30, 2016, cash and cash equivalents totaled $32.1 million, which is projected to fund five Phase 2 clinical trials through 2017.





Zynerba Pharmaceuticals, Inc., (Nasdaq: ZYNE) announced today the pricing of its initial public offering of 3 million shares of common stock at a public offering price of $14.00 per share, before underwriting discounts. All of the shares in the offering are being sold by Zynerba. In addition, Zynerba has granted the underwriters an option to purchase up to 450,000 additional shares of common stock at the public offering price, less the underwriting discount. Zynerba's common stock has been approved for listing on the NASDAQ Global Market and is expected to begin trading under the symbol "ZYNE" on August 5, 2015.

Jefferies LLC and Piper Jaffray & Co. are acting as joint book-running managers for the offering, and Canaccord Genuity Inc. and Oppenheimer & Co. Inc. are acting as co-managers for the offering. This offering is being made only by means of a prospectus.



Extremely low float:

Fundamentals

A table providing the fundamentals of the stock
EPS (TTM) 9/30/2016 | -2.47
P/E Ratio 9/30/2016 | --
Market Cap Micro Cap | 146M
Shares Outstanding 9.95M
Float 7.2M

 

ZYNE
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ZYNE News: Statement of Changes in Beneficial Ownership (4) 10/02/2019 04:06:28 PM
ZYNE News: Zynerba Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference 09/26/2019 11:50:00 AM
ZYNE News: Current Report Filing (8-k) 09/24/2019 07:05:14 AM
ZYNE News: Current Report Filing (8-k) 09/18/2019 07:14:48 AM
ZYNE News: Zynerba Pharmaceuticals Announces Positive Top Line Data from BELIEVE 1 Open Label Phase 2 Study of Zygel™ in Developmental... 09/18/2019 06:30:00 AM
PostSubject
#2020   Lumpy,thanks for that input,the posts that you have dhbuzz 10/21/19 09:47:41 PM
#2019   Dh, there's a few I don't trust, and lumpy9200 10/21/19 06:52:47 PM
#2018   What GW Pharmaceuticals PLC (NASDAQ:GWPH) has achieved with dhbuzz 10/21/19 10:39:44 AM
#2017   Good news,more of this is ahead.This 18.00 est.is dhbuzz 10/21/19 10:20:20 AM
#2016   Zynerba Pharmaceuticals (NASDAQ:ZYNE) initiated with Buy rating and Glider549 10/21/19 09:02:59 AM
#2015   Good grief,I'm not pumping,but it sure is looking dhbuzz 10/19/19 10:08:10 PM
#2014   Yep,I READ THAT IN MY LASTNPOST.EOM dhbuzz 10/18/19 08:42:52 PM
#2013   It's lead development candidate Zygel offers a potential surfgreen 10/18/19 02:04:12 PM
#2012   https://www.proactiveinvestors.com/companies/news/904612/zynerbas-cbd-gel-to-tre dhbuzz 10/18/19 08:19:00 AM
#2011   BIZARROW WORLD looks to be fading away.....OMG dhbuzz 10/17/19 08:32:55 PM
#2010   Same here,good sailors never abandon their ship.I just dhbuzz 10/17/19 07:17:17 PM
#2009   Ditto that, also added a lot of 8's today. ruezim 10/17/19 04:22:14 PM
#2008   $ZYNE$ glad I doubled up w 7’s surfgreen 10/17/19 02:30:41 PM
#2007   https://www.newsfilecorp.com/release/48606 dhbuzz 10/17/19 11:34:12 AM
#2006   I left for awhile as it sank and Glider549 10/17/19 10:01:22 AM
#2005   Sippin' lemonade. eom dhbuzz 10/16/19 08:10:17 PM
#2004   Small shot of reality . eom dhbuzz 10/15/19 09:22:18 PM
#2003   Speculating on the boards is,and will always be dhbuzz 10/14/19 08:25:37 PM
#2002   Well,a new week,will the Z finally move dhbuzz 10/13/19 08:17:58 PM
#2001   Good to see you're still about lumpy. dhbuzz 10/13/19 09:32:22 AM
#2000   Hey dh, lumpy9200 10/12/19 11:52:26 PM
#1999   We just cant seem to hold a gain,but dhbuzz 10/11/19 11:18:31 PM
#1998   I think that GWPH is a short. Leonard McKinley 10/11/19 10:56:08 AM
#1997   I took a break, put it in TYME Glider549 10/11/19 10:32:01 AM
#1996   I suspect that zyne will be fairly quiet Leonard McKinley 10/11/19 05:43:02 AM
#1995   At this point,one would have to admit dhbuzz 10/10/19 08:57:35 PM
#1994   Are you chittin me?! Glider549 10/09/19 12:08:53 PM
#1993   It is?! Glider549 10/07/19 10:13:09 PM
#1992   Oh yea,wanted to ask you about ihub showing dhbuzz 10/07/19 08:16:08 PM
#1991   I grew up in the day of when dhbuzz 10/07/19 10:53:31 AM
#1990   I thought Tom Brady was the GOAT Glider549 10/07/19 10:34:54 AM
#1989   I recently surveyed some goats on how they dhbuzz 10/07/19 08:28:11 AM
#1988   I left, then just started coming back. I had Glider549 10/05/19 12:21:42 AM
#1987   dhbuzz 10/05/19 12:09:06 AM
#1986   WOW...LOL...Glad its not just me.You still in ? dhbuzz 10/05/19 12:09:06 AM
#1985   Yeppers! Glider549 10/04/19 11:07:31 PM
#1984   Glider,are you as confused with this poster as dhbuzz 10/04/19 10:58:05 PM
#1983   Now,after reading your response,if I could I'd dhbuzz 10/04/19 10:34:17 PM
#1982   Not into that nor do I understand what nunaka 10/04/19 04:28:26 PM
#1981   Questions and answers from who to whom? Glider549 10/04/19 08:40:18 AM
#1980   The truth...will set you free. dhbuzz 10/03/19 10:36:42 PM
#1979   In the event you decide to run dhbuzz 10/03/19 09:39:31 PM
#1978   I'm pretty ZYNE positive. Unsettling, though, when nunaka 10/03/19 09:01:17 PM
#1977   Professor Sadleir says the product offers new hope dhbuzz 10/03/19 02:00:58 PM
#1976   https://medicalxpress.com/news/2019-10-cannabidiol-gel-seizures-children-severe. dhbuzz 10/03/19 01:57:23 PM
#1975   This one works much better,lol…https://www.youtube.com/watch?v=ORbseYAkzRM dhbuzz 10/03/19 01:38:24 PM
#1974   Oh my! ...Could it be we are leaving ? dhbuzz 10/03/19 01:15:52 PM
#1973   Glad to do it.Last short info I saw...(posted) dhbuzz 10/03/19 10:58:02 AM
#1972   Glad its helping. Glad to post it .Ive dhbuzz 10/03/19 10:34:32 AM
#1971   I’m echoing the last poster. Reading everything Stockfun1 10/03/19 12:34:27 AM
PostSubject